HRP20040371B1 - Tiofen i tiazolsulfonamidi kao antineoplastični agensi - Google Patents

Tiofen i tiazolsulfonamidi kao antineoplastični agensi

Info

Publication number
HRP20040371B1
HRP20040371B1 HRP20040371AA HRP20040371A HRP20040371B1 HR P20040371 B1 HRP20040371 B1 HR P20040371B1 HR P20040371A A HRP20040371A A HR P20040371AA HR P20040371 A HRP20040371 A HR P20040371A HR P20040371 B1 HRP20040371 B1 HR P20040371B1
Authority
HR
Croatia
Prior art keywords
alkyl
halogen
thiazolesulfonamides
thiopene
amd
Prior art date
Application number
HRP20040371AA
Other languages
English (en)
Inventor
Alfonso@De@Dios
Cora@Sue@Grossman
Philip@Arthur@Hipskind
Ho@Shen@Lin
Karen@Lynn@Lobb
Beatriz@L�pez@de@Uralde@Garmendia
Jose@Eduardo@Lopez
Mary@Margaret@Mader
Michael@Enrico@Richett
Chuan@Shih
Original Assignee
Eli@Lilly@and@Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli@Lilly@and@Company filed Critical Eli@Lilly@and@Company
Publication of HRP20040371A2 publication Critical patent/HRP20040371A2/hr
Publication of HRP20040371B1 publication Critical patent/HRP20040371B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Spoj Formule I naznačen time da X Y je R je izabran iz skupine koja se sastoji od halogena C C alkila i CF R je izabran iz skupine koja se sastoji od halogena NO C C alkila i CF R je H C C alkil C C alkoksi C C alkiltio ili halogen R je izabran iz skupine koju čine Hhalogen C C alkoksi C C alkil COO C C alkil C C alkil prema izboru supstituirani saC C alkoksi cijano C C alkiltio CF S fenil i piridinilom R je halogen C C alkil ili C C alkoksi ilinjihova farmaceutski prihvatljivalužnata adicijska sol Patent sadrži još patentnih zahtjeva
HRP20040371AA 2001-10-25 2004-04-26 Tiofen i tiazolsulfonamidi kao antineoplastični agensi HRP20040371B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25
PCT/US2002/031568 WO2003035629A1 (en) 2001-10-25 2002-10-15 Thiopene- amd thiazolesulfonamides as antineoplastic agents

Publications (2)

Publication Number Publication Date
HRP20040371A2 HRP20040371A2 (en) 2004-08-31
HRP20040371B1 true HRP20040371B1 (hr) 2012-07-31

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040371AA HRP20040371B1 (hr) 2001-10-25 2004-04-26 Tiofen i tiazolsulfonamidi kao antineoplastični agensi

Country Status (34)

Country Link
US (2) US7084170B2 (hr)
EP (1) EP1442030B1 (hr)
JP (1) JP4464681B2 (hr)
KR (1) KR100913471B1 (hr)
CN (1) CN1298709C (hr)
AR (1) AR037248A1 (hr)
AT (1) ATE338033T1 (hr)
AU (1) AU2002334817B2 (hr)
BR (1) BR0212386A (hr)
CA (1) CA2463300C (hr)
CY (1) CY1106247T1 (hr)
DE (1) DE60214413T2 (hr)
DK (1) DK1442030T3 (hr)
EA (1) EA006081B1 (hr)
EC (1) ECSP045078A (hr)
EG (1) EG26021A (hr)
ES (1) ES2269816T3 (hr)
HK (1) HK1068337A1 (hr)
HR (1) HRP20040371B1 (hr)
HU (1) HUP0401638A3 (hr)
IL (2) IL160851A0 (hr)
MX (1) MXPA04003886A (hr)
MY (1) MY130718A (hr)
NO (1) NO20041316L (hr)
NZ (1) NZ531136A (hr)
PE (1) PE20030574A1 (hr)
PL (1) PL208083B1 (hr)
PT (1) PT1442030E (hr)
SI (1) SI1442030T1 (hr)
SV (1) SV2004001367A (hr)
TW (1) TWI281916B (hr)
UA (1) UA75716C2 (hr)
WO (1) WO2003035629A1 (hr)
ZA (1) ZA200403089B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1532133A4 (en) * 2002-06-06 2006-11-15 Smithkline Beecham Corp NF-: B INHIBITORS
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP2364699A1 (en) * 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
EP1859793B1 (en) 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Novel combinational use of a sulfonamide compound in the treatment of cancer
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
JPWO2006090928A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の血管新生阻害物質との新規併用
CA2607359C (en) * 2005-05-13 2011-08-09 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
BRPI0718915A2 (pt) 2006-11-15 2013-12-03 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
US7879884B2 (en) 2007-05-16 2011-02-01 Hoffmann-La Roche Inc. Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团（天津）股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
AU737038B2 (en) * 1996-07-05 2001-08-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302724A (en) * 1990-07-17 1994-04-12 Eli Lilly And Company Antitumor compositions and methods of treatment
EP0513979A1 (en) * 1991-03-26 1992-11-19 Merck & Co. Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
EP0560554A2 (en) * 1992-03-13 1993-09-15 Eli Lilly And Company Antitumor compositions and methods of treatment
WO1998014440A1 (en) * 1996-10-04 1998-04-09 Eli Lilly And Company Antitumor compositions and methods of treatment

Also Published As

Publication number Publication date
US7084170B2 (en) 2006-08-01
CA2463300A1 (en) 2003-05-01
TWI281916B (en) 2007-06-01
US20040198784A1 (en) 2004-10-07
AU2002334817B2 (en) 2008-02-21
JP4464681B2 (ja) 2010-05-19
IL160851A (en) 2009-11-18
HUP0401638A3 (en) 2012-09-28
HUP0401638A2 (hu) 2004-11-29
US7250430B2 (en) 2007-07-31
EP1442030B1 (en) 2006-08-30
CY1106247T1 (el) 2011-06-08
CA2463300C (en) 2011-07-19
ES2269816T3 (es) 2007-04-01
ECSP045078A (es) 2004-06-28
BR0212386A (pt) 2004-07-27
CN1575286A (zh) 2005-02-02
PE20030574A1 (es) 2003-07-03
DE60214413T2 (de) 2007-03-08
MY130718A (en) 2007-07-31
PT1442030E (pt) 2006-12-29
EA006081B1 (ru) 2005-08-25
HRP20040371A2 (en) 2004-08-31
DK1442030T3 (da) 2006-12-27
ATE338033T1 (de) 2006-09-15
IL160851A0 (en) 2004-08-31
MXPA04003886A (es) 2004-07-08
JP2005511547A (ja) 2005-04-28
EP1442030A1 (en) 2004-08-04
NZ531136A (en) 2006-08-31
DE60214413D1 (de) 2006-10-12
EA200400582A1 (ru) 2004-08-26
AR037248A1 (es) 2004-11-03
SV2004001367A (es) 2004-02-24
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
EG26021A (en) 2012-12-10
HK1068337A1 (en) 2005-04-29
US20060223871A1 (en) 2006-10-05
ZA200403089B (en) 2005-04-22
PL368234A1 (en) 2005-03-21
KR20040062583A (ko) 2004-07-07
CN1298709C (zh) 2007-02-07
NO20041316L (no) 2004-03-30
KR100913471B1 (ko) 2009-08-25
UA75716C2 (en) 2006-05-15
WO2003035629A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
HRP20040371B1 (hr) Tiofen i tiazolsulfonamidi kao antineoplastični agensi
FR18C1006I2 (fr) Derives de quinoline ayant un groupe azolyle et derives de quinazoline
HRP20020938B1 (hr) Tropanski derivati korisni u terapiji
RS52119B (en) 4-phenylamino-HINAZOLIN-6-IL-STARCHES
HRP20080226T3 (hr) Derivati kinolina i kinazolina sa afinitetom za receptore tipa 5ht1
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
CA2436846A1 (en) Thioether substituted imidazoquinolines
RS53038B (en) OXADIAZOLA DERIVATIVE Activate Sphingosine-1-Phosphate (SIP)
FI20020503A (fi) Alkyyliaromaattisten yhdisteiden valmistus
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
RS53629B1 (en) CYAN ANTHRANYLAMIDE INSECTICIDES
DK1310502T3 (da) Phosphonocephem-forbindelse
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
HRP20000406B1 (en) Arylpiperazines having activity at the serotonin 1a receptor
RS51545B (en) THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS
ATE346067T1 (de) Carbolinderivate
MEP21308A (en) Ryl alkyl carbamate derivatives production and use thereof in therapy
HRP20040230B1 (hr) Agonisti muskarina
HRPK20040293B3 (hr) Supstituirani benzimidazolski spojevi i njihova primjena u liječenju neoplazma
PT1181294E (pt) Novos derivados e analogos da galantamina
RS52427B (en) ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE
IL150126A0 (en) Novel 4(piperazinyl(8-quinolinyl)methyl) benzamides
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
RS51320B (sr) Derivati imidazohinolina kao veznici a3 receptora adenozina
ATE287397T1 (de) Chinoline derivate und ihre anwendung als antitumor agentien

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20121011

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20131015